GDC-0349 50mg 50mg | Purity Not Available
Adooq Bioscience
GDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin’s lymphoma.
More Information Supplier PageGDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin’s lymphoma.
More Information Supplier PageGDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin’s lymphoma.
More Information Supplier PageGDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin’s lymphoma.
More Information Supplier PageINK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
More Information Supplier PageINK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
More Information Supplier PageINK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
More Information Supplier PageINK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
More Information Supplier PageIstradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson’s disease.
More Information Supplier Page